We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Behind the science
Discover how we're getting ahead
AI and ML power better predictions for patient impact
Digital twin: using advanced technology to accelerate vaccine development
‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
Combining genetics and tech to double success rates
Getting ahead of infectious diseases with advanced technology
Tech for T-cells single cell RNA seq measures shifts in immune cells to pinpoint causes of disease
Fresh insights could finally help us tackle RSV
The ‘tripledemic’ will hit older people hard this winter – but there are things we can all do to reduce the impact
Life at GSK
How we help people thrive
Diversity, equity and inclusion
Positively impacting society and the planet
Pricing and access
We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.
Global health and health security
We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.
Diversity, equity and inclusion
Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.
We are working towards a net zero impact on climate and a net positive impact on nature by 2030, across our full value chain.
Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.
In the spotlight
GSK on social
Clinical trials commonly enrol participants based on census data. Our experience shows us there’s a better way to improve diversity in clinical trials, given that some diseases disproportionately impact specific patient groups. Learn more: gsk.to/40Buxb8Twitter @GSK Feb 06
This #WorldCancerDay, discover how we’re getting ahead of #cancer together by exploring checkpoints along the CD226 axis and aiming to maximise patient survival through transformational immuno-oncology therapies. gsk.to/3juEBlsTwitter @GSK Feb 04
Twitter @GSK Feb 02
#Investors: Join GSK CEO Emma Walmsley and other members of our leadership team for our full year and Q4 2022 live results webcast at 11:00 GMT, 06:00 EST. $GSK
Please read this cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures for our FY 2022 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. $GSK gsk.to/3jh506f
By working together, we can help #endNTDs. This #WorldNTDDay, we’re proud to be extending our donation commitment for soil-transmitted helminthiasis (STH) to 2030. From 2026-2030, we’ll donate up to 100 million doses of our medicines for STH per year. #100percentCommittedTwitter @GSK Jan 30